Regeneron(REGN) Prnewswire·2025-01-23 20:01Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Regeneron Pharmaceuticals due to allegations of misleading statements and violations of federal securities laws related to the pricing and sales of its Eylea drug [2][4][5]. Group 1: Allegations Against Regeneron - The complaint alleges that Regeneron made false and misleading statements regarding credit card fee payments to distributors, which were not disclosed as price concessions [4]. - It is claimed that these undisclosed payments led to inflated reported sales of Eylea and overstated average selling prices (ASP) reported to federal agencies, violating the False Claims Act [4][5]. - The U.S. Department of Justice filed a complaint against Regeneron, stating that the company failed to report millions in discounts, which resulted in inflated Medicare reimbursements [5]. Group 2: Financial Impact and Stock Performance - Following the DOJ announcement, Regeneron's stock price fell by 904.70 on April 12, 2024, with unusually heavy trading volume [6]. - On October 31, 2024, Regeneron reported third-quarter 2024 financial results, revealing only a 3% increase in U.S. net sales for Eylea compared to the previous year, with sales of Eylea HD at 84.59, or 9.2%, to close at $838.20 per share on the same day, indicating a significant market reaction to the disappointing sales figures [7].